Albuterol Sulfate Solution Shortage Update
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Albuterol Sulfate Solution is currently listed in shortage by the FDA, with the sole manufacturer reporting availability amid high demand.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 23, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Albuterol Sulfate Solution.
What's in Shortage
The drug in shortage is Albuterol Sulfate Solution, with the brand name ALBUTEROL SULFATE. It is a solution dosage form and belongs to the therapeutic categories of Pulmonary/Allergy and Pediatric. The shortage status is current, with the initial posting date of 10/25/2022 and last updated on 04/20/2026.
Which Manufacturers Are Affected
Nephron Pharmaceuticals Corporation is the affected manufacturer. Their availability status is available, though demand remains high and additional supply can be produced as needed. The presentation is Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 0487-9901-30). Contact information for the manufacturer is 800-443-4313.
Why There's a Shortage
No specific reason was given for the shortage.
What Patients Should Do
Patients who depend on this medication should talk to their pharmacist about availability and options. They can also contact the manufacturer directly for more information. Please remember that patients should consult their healthcare provider for any guidance on their medication needs.
Source
This information is attributed to the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,158 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 23, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.